Neoadjuvant Chemotherapy in Patients With Moderate Risk Mid Rectal Cancer
Status:
Enrolling by invitation
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether 3 months of neoadjuvant CapOx is
non-inferior to neoadjuvant radiotherapy in patients with moderate risk CRM"-" mid rectal
cancer.